Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Prevalence of Folic Acid Deficiency and Cost Effectiveness of Folic Acid Testing: A Single Center Experience

Karina Diaz, Zhu Na, Sorab Gupta, MD, Vikram Arya, Lourdes Martinez, Supreet Dhaliwal, Nora Ajdir, Bhavita Gaglani, Shradha Ahuja, MD, Ilmana Fulger, MD

Blood (2018) 132 (Supplement 1): 4878.

https://doi.org/10.1182/blood-2018-99-111607

Published: 2018

Journal Articles

Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors

Remco J Molenaar, Tomas Radivoyevitch, Aziz Nazha, MD, Anjali S. Advani, MD, Aaron T. Gerds, MDMS, Jaroslaw P. Maciejewski, PhD MD FACP, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS, Matt Kalaycio, MD, Sudipto Mukherjee, MD PhD MPH

Blood (2017) 130 (Supplement 1): 2871.

https://doi.org/10.1182/blood.V130.Suppl_1.2871.2871

Published: 2017

Journal Articles

Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia

Blood (2016) 128 (22): 64.

https://doi.org/10.1182/blood.V128.22.64.64

Published: 2016

Journal Articles

Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results

Blood (2015) 126 (23): 4376.

https://doi.org/10.1182/blood.V126.23.4376.4376

Published: 2015

Journal Articles

High Incidence of Neurological Complications in Patients with Sickle Anemia Disease Undergoing Related Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Early Diagnosis and Treatment Can Chance the Prognosis

Ricardo Helman, Juliana Folloni Fernandes, PhD, Michelli Silva Diniz, RN, Fabio R. Kerbauy, MD PhD, Lucila Nassif Kerbauy, Eduardo Cerello Chapchap, Melina Brumatti, Nathalia da Silva Halley Neves, Alessandra Prandini Azambuja, Jose Mauro Kutner, MD PhD, Andreza Feitosa Ribeiro, MD PhD, Nelson Hamerschlak, MD PhD

Blood (2014) 124 (21): 5941.

https://doi.org/10.1182/blood.V124.21.5941.5941

Published: 2014

Journal Articles

The Incidence Of Posterior Reversible Encephalopathy Syndrome Is Increased In BMT For Haemoglobinopathies

David Thompson, Yvonne Harrington, RCN, Josu de la Fuente, PhD, FRCP, MRCPCH, FRCPath

Blood (2013) 122 (21): 4579.

https://doi.org/10.1182/blood.V122.21.4579.4579

Published: 2013

Journal Articles

The Use Of Neuropathic Pain Drugs In Patients With Sickle Cell Disease Is Associated With Older Age and Female Gender

Amanda M Brandow, DO, MS, Rebecca A. Farley, BS, Amrit Karki, PhD, Raymond G Hoffmann, Julie A. Panepinto, MD, MSPH

Blood (2013) 122 (21): 1717.

https://doi.org/10.1182/blood.V122.21.1717.1717

Published: 2013

Journal Articles

Cerebral Venous Thrombosis in Adolescents and Young Adults with Classical Hodgkin Lymphoma

Poornima Kumar, MBBS, Rebekah Ahmed, MBBS, Renu Riat, MBBS, Kirit M Ardeshna, MD, Stephen Daw, MBChb

Blood (2012) 120 (21): 4784.

https://doi.org/10.1182/blood.V120.21.4784.4784

Published: 2012

Journal Articles

Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests,

Donald M. Arnold, MD, Theodore E. Warkentin, MD, James W. Smith, BSc, Aliya Esmail, Sadiya Kukaswadia, MD, Lori Dewar, John G. Kelton, MD, FRCPC

Blood (2011) 118 (21): 3304.

https://doi.org/10.1182/blood.V118.21.3304.3304

Published: 2011

Journal Articles

Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Celina Ledesma, B.S., Kirk Culotta, PharmD, Elizabeth J. Shpall, MD, Stefan O. Ciurea, MD, Amin M Alousi, MD, Marcos De Lima, MD, Uday Popat, MD, Deborah A Thomas, MD, Richard E. Champlin, MD, Borje S Andersson, MD

Blood (2010) 116 (21): 3484.

https://doi.org/10.1182/blood.V116.21.3484.3484

Published: 2010

Journal Articles

A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

Monica Bhatia, MD, Mark B Geyer, AB, Courtney Baker, RN, MSN, PNP, Erin Morris, RN, BSN, Deirdre Duffy, BS, Diane George, MD, James H Garvin, Jr., MD, PhD, Prakash Satwani, MD, Joseph Schwartz, MD, Sandra Foley, CPNP, Ria Hawks, CPNP, Elana Hamburger-Smilow, CPNP, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 3504.

https://doi.org/10.1182/blood.V116.21.3504.3504

Published: 2010

Journal Articles

Screening for Potential Covariates Influencing the Pharmacokinetics of Intravenous Busulfan: Results From a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation

Zeinab Daher Abdi, Angelo Paci, PharmD, PhD, Despina Moshous, Jean-Hugues Dalle, MD, Nathalie Bleyzac, Benedicte Neven, Claire Galambrun, Véronique Kemmel, Aurélie Pétain, Sophie Broutin, Laurent Nguyen, Gilles Vassal

Blood (2010) 116 (21): 1811.

https://doi.org/10.1182/blood.V116.21.1811.1811

Published: 2010

Journal Articles

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies.

Partow Kebriaei, MD, Timothy Madden, BS, PHARMD, Reza Kazerooni, RPH, Elizabeth Shpall, MD, Xuemei Wang, MS, Peter Thall, MD, Chitra Hosing, MD, Muzaffar Qazilbash, MD, Uday Popat, MD, Celina Ledesma, BS, Issa Khouri, MD, Richard Champlin, MD, Roy Jones, MD, Borje S. Andersson, MD

Blood (2009) 114 (22): 3415.

https://doi.org/10.1182/blood.V114.22.3415.3415

Published: 2009

Journal Articles

Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by Targeted Intravenous Busulfan) in Allogeneic Hematopoietic Cell Transplantation: Preliminary Results of a Prospective Clinical Trial.

Andrew R. Rezvani, MD, Jeannine S. McCune, PhD, Ami Batchelder, Barry E. Storer, PhD, George B. McDonald, MD, H. Joachim Deeg, MD

Blood (2009) 114 (22): 1175.

https://doi.org/10.1182/blood.V114.22.1175.1175

Published: 2009

Journal Articles

Relationship of Targeted Busulfan Exposure to Engraftment in Children Undergoing Myeloablative Matched Sibling Donor Transplantation for Sickle Cell Disease.

Marianne E. McPherson, MD, Don Hutcherson, RPh, Ellen Olson, CPNP, Ann Haight, MD, John Horan, MD, MPH, Kuang-Yueh Chiang, MD, PhD

Blood (2008) 112 (11): 2152.

https://doi.org/10.1182/blood.V112.11.2152.2152

Published: 2008

Journal Articles

Outcome of Hematopoietic Cell Transplantation in Children with Sickle Cell Disease, a Single Center’s Experience.

Suvankar Majumdar, MD, Zachary Robertson, MD, Anita Robinson, CFNP, Sarah Starnes, CFNP, Rathi Iyer, MD, Gail Megason, MD

Blood (2007) 110 (11): 1112.

https://doi.org/10.1182/blood.V110.11.1112.1112

Published: 2007

Journal Articles

High Dose Glucocorticoids Potentiate the Reponse to Erythropoietin.

Maged Khalil, MD, Zili He, MD, Ashish Sangal, MD, Aref Agheli, MD, Alka Arora, MD, Theresa Dumlao, MD, Seema Naik, MD, Elizabeth Chiu, Ha,PHARM.D., Madhumati Kalavar, MD, William Steier, MD

Blood (2006) 108 (11): 3775.

https://doi.org/10.1182/blood.V108.11.3775.3775

Published: 2006

Journal Articles

Toxicity and Early Response after Intravenous (IV) Busulfan (Bu) Plus Melphalan (Mel) Conditioning for Autologous Stem Cell Transplantation (SCT) in Patients (pts) with Multiple Myeloma (MM).

Partow Kebriaei, MD, Sergio Giralt, MD, Timothy L. Madden, Ph.D., Neil Thapar, Ph.D., Elizabeth J. Shpall, M.D., Chitra Hosing, M.D., Muzaffar H. Qazilbash, M.D., Daniel R. Couriel, M.D., Uday Popat, M.D., Peter F. Thall, Ph.D., Richard E. Champlin, M.D., Roy Jones, M.D./Ph.D., Borje S. Andersson, M.D./Ph.D.

Blood (2006) 108 (11): 2943.

https://doi.org/10.1182/blood.V108.11.2943.2943

Published: 2006

Journal Articles

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Carolyn Blasdel, MA, RN, FNP, Yanfeng Wang, PhD, Theodore Lagattuta, BS, Brian Druker, MD, Laurie Letvak, MD, Merrill Egorin, MD FACP

Blood (2006) 108 (11): 4820.

https://doi.org/10.1182/blood.V108.11.4820.4820

Published: 2006

Journal Articles

Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein, Lnk

Hitoshi Takizawa, Chiyomi Kubo-Akashi, Ikuo Nobuhisa, Sang-Mo Kwon, Masanori Iseki, Tetsuya Taga, Kiyoshi Takatsu, Satoshi Takaki

Blood (2006) 107 (7): 2968–2975.

https://doi.org/10.1182/blood-2005-05-2138

Published: 2006

NARROW

Prevalence of Folic Acid Deficiency and Cost Effectiveness of Folic Acid Testing: A Single Center Experience

Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors

Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia

Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results

High Incidence of Neurological Complications in Patients with Sickle Anemia Disease Undergoing Related Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Early Diagnosis and Treatment Can Chance the Prognosis

The Incidence Of Posterior Reversible Encephalopathy Syndrome Is Increased In BMT For Haemoglobinopathies

The Use Of Neuropathic Pain Drugs In Patients With Sickle Cell Disease Is Associated With Older Age and Female Gender

Cerebral Venous Thrombosis in Adolescents and Young Adults with Classical Hodgkin Lymphoma

Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests,

Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL).

A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

Screening for Potential Covariates Influencing the Pharmacokinetics of Intravenous Busulfan: Results From a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies.

Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by Targeted Intravenous Busulfan) in Allogeneic Hematopoietic Cell Transplantation: Preliminary Results of a Prospective Clinical Trial.

Relationship of Targeted Busulfan Exposure to Engraftment in Children Undergoing Myeloablative Matched Sibling Donor Transplantation for Sickle Cell Disease.

Outcome of Hematopoietic Cell Transplantation in Children with Sickle Cell Disease, a Single Center’s Experience.

High Dose Glucocorticoids Potentiate the Reponse to Erythropoietin.

Toxicity and Early Response after Intravenous (IV) Busulfan (Bu) Plus Melphalan (Mel) Conditioning for Autologous Stem Cell Transplantation (SCT) in Patients (pts) with Multiple Myeloma (MM).

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein, Lnk

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only